Ikarovec is a company that develops treatments for complex diseases. The company focuses on producing treatments that they describe as elegant.

Ikarovec

The company has an early stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms) and ocular hypertension. 

Future Planet Capital

LifeArc

UK Innovation & Science Seed Fund

Parkwalk Advisors

ikarovec 

Will I see you in Boston? 👀

📣 I am excited to be speaking at the 5th Gene Therapy for Ophthalmic Disorders Summit this September 10-12 in Boston, MA! 

💡 On Day 2 I will be presenting 'Insights from Preclinical Disease Modelling in Ophthalmic Gene Therapy' and showcasing the phenomenal amount of work produced by the research team at ikarovec 

Here’s the link: https://ter.li/xs2c2a 

👋 Feel free to reach out to introduce yourself or to arrange a catch-up!  ☕ 

#ikarovec #genetherapy #ophthalmology #fightingblindness

🔬 After a short leave of absence ikarovec image of the month has returned!
 
😎 Over August, we will be dialling back our LinkedIn activities for a well earned rest.

👀 But keep your eyes peeled in September for a big announcement…📣

#genetherapy #biotechstartup #AMD #ophthalmology #microscopy #H&E #summerholidays

Ikarovec’s CSO Katie Binley took part in the One Nucleus On Helix panel discussion today all about the Boston Bootcamp. 

It was a great opportunity for the panel to share learnings, challenges and opportunities from the experience with the Cambridge UK life sciences ecosystem.

This week ikarovec  CSO Katie Binley was thrilled to be selected to give a presentation at the British Society for Gene and Cell Therapy (BSGCT) in the CNS & Ocular session chaired by Carly Bliss & @Michelle McClements. 

It was a honour to speak alongside Simon Waddington (development of a much needed gene therapy to treat dopamine transporter deficiency , hDAT) Jasmina Cehajic Kapetanovic (clinical gene therapies for inherited retinal diseases including RPGR, optogenetics and robotic assisted surgery), @Ralph Hector (a self regulating gene therapy for Rett Syndrome) and @Katie Greed who gave a passionate and personal presentation of living with Phelon McDermid Syndrome (PMS)

📣 Katie Binley, ikarovec’s Chief Scientific Officer, will give an oral presentation on Tuesday 18th June at the Annual British Society for Gene and Cell Therapy (BSGCT) in Oxford at the Saïd Business School, University of Oxford. 

The talk will focus on the exciting scientific achievements at ikarovec from the design of a next generation bicistronic AAV-based gene therapy to treat geographic atrophy through to the demonstration of robust efficacy in key proof-of-concept ocular models.   

#genetherapy  #AMD #ophthalmology

Ikarovec is excited to be part of the Cell and Gene Therapy Catapult Consortium, partnering with Croda and UCL, to advance the development of formulation buffers for their lead AAV vector targeting GA.

 🔍 💡 🔬

Metric
Company Name	Ikarovec
Symbol
MSH ID	COM:IKAROVEC
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	GB
Stage
Employee Count	6
Website	ikarovec.com
LinkedIn	ikarovec
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IKAR

COM:IKAROVEC

Ikarovec

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue